Proteome Sciences plc (AIM:PRM) is pleased to announce that at its General Meeting held earlier today, all resolutions were duly passed.
Accordingly, and as set out in the announcement dated 31 October 2016 (the “Announcement”), the Company now has the requisite authorities to complete the second tranche of the placing and subscription of 66,258,100 new ordinary shares of 1 pence each in the capital of the Company ("Ordinary Shares") with new and existing shareholders at a price of 5 pence per Ordinary Share to raise, in aggregate, £3.3 million before expenses (the "Fundraise").
The net proceeds of the Fundraise will be used to accelerate the Company's evolution into a premium contract, service-based biomarker business, underpinned with a bioinformatics capability whilst ensuring that the Company has the capacity to meet Thermo Fisher Scientific's further demand for its TMT reagents.
As an amendment to the Announcement, Vulpes Life Science Fund (a participant in the Fundraise of which Martin Diggle, Non-Executive Director of the Company, is a director and beneficiary) is expecting to delay its funding by one week due to the completion of a corporate restructuring of its Investment Manager in Singapore. Accordingly, the 20,664,754 new Ordinary Shares issued pursuant to the second tranche of the Fundraise are now expected to be admitted to trading on AIM at 8.00 a.m. on 16 December 2016 ("Admission"). Following Admission, the Company will have 294,324,832 Ordinary Shares in issue, all with voting rights. The Company does not hold any shares in treasury.
The above figure of 294,324,832 Ordinary Shares may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure and Transparency Rules.